Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)

被引：0
|
作者：
Bianchini, Diletta
Sandhu, Shahneen Kaur
Cassidy, Amy Mulick
Zivi, Andrea
Mezynski, Janusz
Mukherji, Deborah
Pezaro, Carmel Jo
Reid, Alison Helen
Oommen, Nikhil Babu
Olmos, David
Omlin, Aurelius Gabriel
Sarvadikar, Ajit
Thompson, Emilda
Hunt, Joanne
Sheridan, Elizabeth
Attard, Gerhardt
De Bono, Johann Sebastian
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Fdn Trust, Sutton, Surrey, England
[4] Royal Marsden Hosp, Dublin, Ireland
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate
    Hung, Sheng-Chun
    Wang, Shian-Shiang
    Li, Jian-Ri
    Chen, Mei-Chih
    Yang, Cheng-Kuang
    Chen, Chuan-Shu
    Ho, Hao-Chung
    Chiu, Kun-Yuan
    Cheng, Chen-Li
    Chang, Chao-Hsiang
    Ou, Yen-Chuan
    ANTICANCER RESEARCH, 2018, 38 (09) : 5429 - 5436
  • [3] Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
    Leibowitz-Amit, R.
    Templeton, A. J.
    Omlin, A.
    Pezaro, C.
    Atenafu, E. G.
    Keizman, D.
    Vera-Badillo, F.
    Seah, J. -A.
    Attard, G.
    Knox, J. J.
    Sridhar, S. S.
    Tannock, I. F.
    de Bono, J. S.
    Joshua, A. M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 657 - 662
  • [4] CLINICAL ACTIVITY OF ABIRATERONE ACETATE (AA) AFTER PROGRESSION ON MDV3100 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Noonan, K.
    Ellard, S.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [5] PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate resistant prostate cancer (mCRPC).
    Ramalingam, Sundhar
    Humeniuk, Michael Sandon
    Hu, Rachel
    Rasmussen, Julia
    Healy, Patrick
    Wu, Yuan
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
    Caffo, O.
    Maines, F.
    De Giorgi, U.
    Fratino, L.
    Lo Re, G.
    Zagonel, V.
    D'Angelo, A.
    Donini, M.
    Verderame, F.
    Ratta, R.
    Procopio, G.
    Campadelli, E.
    Massari, F.
    Gasparro, D.
    Ermacora, P.
    Messina, C.
    Giordano, M.
    Alesini, D.
    Conteduca, V.
    Veccia, A.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [8] Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.
    Lopez-Campos, Fernando
    Gomez-Iturriaga, Alfonso
    Llacer Perez, Casilda
    Henriquez, Ivan
    Peleteiro, Paula
    Lozano, Rebeca
    Castano, Ana
    Romero-Laorden, Nuria
    Molina-Cerrillo, Javier
    Alvarez-Rodriguez, Sara
    Piquer, Teresa
    Navarro-Castellon, Joaquin
    Jose Conde-Moreno, Antonio
    Ramirez-Backhaus, Miguel
    Barrionuevo, Patricia
    Garcia, Raquel
    de los Llanos Perez-Haro, Maria
    Castro, Elena
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Burgio, Salvatore L.
    Conteduca, Vincenza
    Rudnas, Britt
    Carrozza, Francesco
    Campadelli, Enrico
    Bianchi, Emanuela
    Fabbri, Paolo
    Montanari, Marco
    Carretta, Elisa
    Menna, Cecilia
    De Giorgi, Ugo
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 39 - 43
  • [10] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
12345